Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.

Thumbnail
View/Open
Published version (122.2Kb)
Date
2017-04
ICR Author
Larkin, James
Marsden,
Author
Bowyer, S
Prithviraj, P
Lorigan, P
Larkin, J
McArthur, G
Atkinson, V
Millward, M
Khou, M
Diem, S
Ramanujam, S
Kong, B
Liniker, E
Guminski, A
Parente, P
Andrews, MC
Parakh, S
Cebon, J
Long, GV
Carlino, MS
Klein, O
Show allShow less
Type
Journal Article
Metadata
Show full item record
URI
https://repository.icr.ac.uk/handle/internal/636
DOI
https://doi.org/10.1038/bjc.2017.59
Collections
  • Clinical Studies
Subject
Humans
Melanoma
Skin Neoplasms
CTLA-4 Antigen
Programmed Cell Death 1 Receptor
Ipilimumab
Research team
Melanoma and Kidney Cancer
Language
eng
License start date
2017-04
Citation
British journal of cancer, 2017, 116 (8), pp. e15 - ?

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.